Join forces at the Expo! JD Health (06618) reached a strategic cooperation with Merck to prioritize JD Health for the launch of new drugs in the next three years
The Zhitong Finance App learned that on November 6, during the 9th China International Import Expo, JD Health (06618) and Merck Healthcare signed a strategic cooperation agreement. The two sides will establish a long-term and stable strategic cooperation mechanism with the launch of new innovative drugs as the core of cooperation. In the next three years, JD Health will become the preferred channel for the launch of new Merck Healthcare drugs. The two sides will also explore more cooperation in the fields of chronic disease management, online consultation, and patient follow-up to accelerate the “last mile” of innovative drugs reaching patients.
Relying on the global innovative drug cooperation network and efficient pharmaceutical supply chain, JD Health continues to consolidate its absolute leading edge in the field of innovative drug launches, promote the launch of more good global drugs in JD and reach patients quickly, making “buy the world's best drugs in JD” the first choice for users to buy drugs. Cao Dong, SEC member of JD Group and CEO of JD Health, said, “Ultimately, the value of innovative drugs must be realized through patient accessibility and standardized use. JD Health will make full use of its capabilities in the pharmaceutical supply chain, internet medical care, and digital services to promote innovative drugs to reach patients in need faster and more widely. We look forward to further opening up the full link from the launch of new products, professional diagnosis and treatment to medication services and long-term follow-up through this cooperation, so that more patients can easily and safely receive high-quality medical and health services.”
Andre Musto, managing director of Merck China Healthcare, said, “Truly meaningful innovation lies not only in scientific breakthroughs themselves, but also in whether they can be transformed into solutions that are accessible to patients more quickly and with wider coverage. Through ecological co-construction, Merck hopes to join hands with JD Health to accompany patients throughout their health journey, so that more Chinese patients can actually benefit from medical progress.”
The previous cooperation between the two sides has demonstrated the value of JD Health as the “first platform for the launch of new drugs on the entire network”. After Merck's innovative drug pimitinib for the treatment of giant cytoma of the tendon sheath was launched at JD Health, patients with rare diseases purchased the drug through the platform in the first month. For innovative drugs for rare tumors, where the number of patients is limited and traditional channels are difficult to cover, this launch not only reflects the accessibility efficiency of online channels, but also confirms patients' real demand for convenient and trustworthy drug purchase channels.
Rooted in China for more than 90 years, Merck is turning “Chinese speed” into an innovative advantage through local capabilities covering R&D, clinical, supply, and commercialization: on the one hand, promoting global innovation achievements to benefit Chinese patients more quickly, and on the other hand, making innovations originating in China serve more patients through local ecological cooperation.
Relying on JD Health's closed-loop service capabilities covering medicine, testing, diagnosis, and medicine, the two sides will promote innovative drugs to enter online channels faster, and further connect professional consultation, online consultation, medication services and long-term follow-up, which will not only help patients improve the availability of innovative drugs; professional services and follow-up mechanisms established around medication use will help enhance the continuity of treatment and patient compliance.
In the future, JD Health and Merck will continue to deepen collaboration, so that more innovative drugs can quickly cross the “last mile” from approval and marketing to patient use, and help patients obtain more convenient, continuous, and sustainable health management support.